…
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -34.77M | -25.50M | -30.09M | -26.96M | -20.61M |
| Net income | -34.77M | -25.50M | -30.09M | -26.23M | -20.61M |
| Selling general administrative | 15.96M | 13.50M | 14.04M | 12.61M | 11.31M |
| Selling and marketing expenses | - | - | 14.01M | - | - |
| Gross profit | -0.02M | -0.02M | -0.02M | - | - |
| Reconciled depreciation | 0.02M | 0.02M | 0.01M | 0.01M | 0.02M |
| Ebit | -37.14M | -27.62M | -31.38M | -27.70M | -20.52M |
| Ebitda | -37.12M | -27.60M | -31.35M | -27.69M | -20.50M |
| Depreciation and amortization | 0.02M | 0.02M | 0.02M | 0.01M | 0.02M |
| Non operating income net other | - | - | - | 0.73M | -0.09M |
| Operating income | -37.14M | -27.62M | -31.38M | -27.69M | -20.52M |
| Other operating expenses | 37.14M | 27.62M | 31.38M | 27.69M | 20.52M |
| Interest expense | - | - | - | -0.01M | 0.09M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | 2.38M | 4.05M | 3.78M | 0.88M | - |
| Net interest income | 2.38M | 4.05M | 3.78M | 0.88M | - |
| Income tax expense | - | - | - | -0.73M | 0.09M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 37.14M | 27.62M | 31.38M | 27.69M | 20.52M |
| Cost of revenue | 0.02M | 0.02M | 0.02M | - | - |
| Total other income expense net | 2.37M | 2.12M | 1.28M | 0.73M | -0.09M |
| Net income from continuing ops | -34.77M | -25.50M | -29.83M | -26.96M | -20.61M |
| Net income applicable to common shares | - | - | - | -26.96M | -20.61M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 47.61M | 76.44M | 96.25M | 123.53M | 141.26M |
| Other current assets | 4.32M | 3.37M | 3.65M | 2.42M | 1.19M |
| Total liab | 8.26M | 4.97M | 5.24M | 5.57M | 3.13M |
| Total stockholder equity | 39.35M | 71.48M | 91.02M | 117.96M | 138.14M |
| Other current liab | 3.96M | 4.29M | 4.43M | 2.60M | 1.41M |
| Common stock | 1.55M | 23.49M | 22.79M | 22.79M | 22.79M |
| Capital stock | 1.55M | 23.49M | - | 22.79M | 22.79M |
| Retained earnings | -246.56M | -211.79M | -186.29M | -156.19M | -129.23M |
| Other assets | - | - | - | 0.64M | 0.00M |
| Cash | 41.30M | 71.08M | 88.57M | 110.89M | 136.38M |
| Total current liabilities | 8.26M | 4.97M | 5.24M | 5.57M | 3.13M |
| Net debt | -41.30M | -71.08M | -88.57M | -110.89M | -136.38M |
| Other stockholder equity | 284.37M | 259.78M | 254.51M | 250.78M | 244.58M |
| Property plant equipment | - | - | - | - | 0.02M |
| Total current assets | 45.62M | 74.46M | 92.22M | 118.20M | 141.24M |
| Long term investments | - | 0.00M | - | 4.70M | - |
| Net tangible assets | - | - | - | 117.96M | 137.55M |
| Net receivables | - | - | -0.00M | 0.74M | 1.07M |
| Inventory | - | - | 1.49M | 4.14M | 2.60M |
| Accounts payable | 4.29M | 0.68M | 0.81M | 2.96M | 1.72M |
| Accumulated other comprehensive income | - | - | 0.00M | - | -0.58M |
| Common stock total equity | - | - | - | 22.79M | 22.79M |
| Retained earnings total equity | - | - | - | -156.19M | -129.23M |
| Non currrent assets other | 1.99M | 1.99M | 2.32M | 0.64M | 0.00M |
| Non current assets total | 1.99M | 1.99M | 4.03M | 5.33M | 0.02M |
| Capital lease obligations | - | - | - | - | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.02M | -2.02M | -4.73M | -0.01M |
| Change to liabilities | - | - | - | 2.44M | 0.13M |
| Total cashflows from investing activities | -0.02M | -0.02M | -0.01M | -4.73M | -0.01M |
| Total cash from financing activities | 0.00M | 3.67M | -1.48M | 0.00M | 113.30M |
| Change to operating activities | - | - | - | -1.85M | -1.28M |
| Net income | -34.77M | -25.50M | -30.09M | -26.96M | -20.61M |
| Change in cash | -29.79M | -17.38M | -22.43M | -25.49M | 96.82M |
| Begin period cash flow | 71.19M | 88.57M | 111.00M | 136.49M | 39.66M |
| End period cash flow | 41.41M | 71.19M | 88.57M | 111.00M | 136.49M |
| Total cash from operating activities | -29.76M | -21.03M | -20.94M | -20.76M | -16.47M |
| Issuance of capital stock | - | - | - | 0.00M | 69.67M |
| Depreciation | 0.02M | 0.02M | 0.02M | 0.01M | 0.02M |
| Other cashflows from investing activities | - | - | -0.01M | -4.70M | - |
| Change to inventory | -0.98M | -0.61M | 2.54M | - | - |
| Change to account receivables | - | - | 0.74M | - | - |
| Sale purchase of stock | - | 0.00M | -1.48M | - | 44.21M |
| Other cashflows from financing activities | - | 3.67M | -1.47M | -4.73M | 43.64M |
| Change to netincome | - | - | - | 6.79M | 5.27M |
| Capital expenditures | 0.02M | 0.02M | 0.01M | 0.03M | 0.01M |
| Cash flows other operating | - | - | - | -3.04M | -1.63M |
| Cash and cash equivalents changes | - | - | - | -25.49M | 96.82M |
| Change in working capital | 2.35M | 0.45M | 1.52M | -0.60M | -1.16M |
| Stock based compensation | 2.65M | 2.29M | 4.62M | 6.79M | 5.27M |
| Other non cash items | 2.35M | 1.72M | 2.99M | 0.00M | 26.96M |
| Free cash flow | -29.79M | -21.05M | -20.95M | -20.79M | -16.48M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ATOS Atossa Genetics Inc |
-0.15 8.86% |
1.59 | - | 7.04 | 1872.06 | 0.92 | 3287.25 | 2.01 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
448 NW Market Street, Seattle, WA, United States, 98107
206 588 0256
16
| Name | Title | Year Born |
|---|---|---|
| Dr. Steven C. Quay FCAP, M.D., Ph.D. | Chairman, CEO & Pres | 1951 |
| Mr. Kyle Guse CPA, Esq., CPA | CFO, Gen. Counsel & Sec. | 1964 |
| Ms. Heather Rees | VP of Fin. & Accounting | NA |
| Ms. Delly Behen P.H.R. | VP of Admin. & HR | NA |
| Ms. Janet Rose Rea MSPH, RAC | Sr. VP of Regulatory, Quality & Clinical Affairs | NA |
| Dr. Richard Graydon M.D., Ph.D. | Interim Chief Medical Officer | NA |
| Dr. Steven C. Quay FCAP, M.D., Ph.D. | Chairman, CEO & President | 1951 |
| Ms. Heather Rees CPA | Senior VP of Finance & Principal Accounting Officer | 1973 |
| Ms. Delly Behen P.H.R. | Senior Vice President of Administration & HR | NA |
| Mr. Eric Van Zanten | Vice President of Investor & Public Relations | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.